Tyrosine Phosphorylation of the E3 Ubiquitin Ligase TRIM21 Positively Regulates Interaction with IRF3 and Hence TRIM21 Activity by Stacey, Kevin B. et al.
Tyrosine Phosphorylation of the E3 Ubiquitin Ligase




1,2, Caroline A. Jefferies
1*
1Department Molecular and Cellular Therapeutics, Royal College Surgeons in Ireland Research Institute, Royal College of Surgeons in Ireland, Dublin, Ireland, 2Centenary
Institute and Arthur William (AW) Morrow Gastroenterology and Liver Centre, Camperdown, Australia,
Abstract
Patients suffering from Systemic Lupus Erythematous (SLE) have elevated type I interferon (IFN) levels which correlate with
disease activity and severity. TRIM21, an autoantigen associated with SLE, has been identified as an ubiquitin E3 ligase that
targets the transcription factor IRF3 in order to turn off and limit type I IFN production following detection of viral and
bacterial infection by Toll Like Receptors (TLRs). However, how the activity of TRIM21 is regulated downstream of TLRs is
unknown. In this study we demonstrate that TRIM21 is tyrosine phosphorylated following TLR3 and TLR4 stimulation,
suggesting that its activity is potentially regulated by tyrosine phosphorylation. Using Netphos, we have identified three key
tyrosines that are strongly predicted to be phosphorylated, two of which are conserved between the human and murine
forms of TRIM21, at residues 343, 388, and 393, all of which have been mutated from tyrosine to phenylalanine (Y343F,
Y388F, and Y393F). We have observed that tyrosine phosphorylation of TRIM21 only occurs in the substrate binding PRY/
SPRY domain, and that Y393, and to a lesser extent, Y388 are required for TRIM21 to function as a negative regulator of IFN-
b promoter activity. Further studies revealed that mutating Y393 to phenylalanine inhibits the ability of TRIM21 to interact
with its substrate, IRF3, thus providing a molecular explanation for the lack of activity of Y393 on the IFN-b promoter. Our
data demonstrates a novel role for tyrosine phosphorylation in regulating the activity of TRIM21 downstream of TLR3 and
TLR4. Given the pathogenic role of TRIM21 in systemic autoimmunity, these findings have important implications for the
development of novel therapeutics.
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Introduction
Mechanisms that regulate and limit protective immune
responses are critical in the prevention of excessive and
pathological production of type I IFNs or pro-inflammatory
cytokines. The concept that ubiquitin-mediated degradation of key
targets on the pathway may be important in this context is not
new, the canonical example being the regulation of NF-kB
activation via the activity of the E3 ubiquitin ligases A20 and
CYLD. Both A20 and CYLD limit the duration of NFkB
activation via a ubiquitin editing mechanism. A20 for example has
dual deubiquitinating and ubiquitinating activity and replaces
K63-linked ubiquitin chains on two key signalling proteins on the
NFkB pathway, IRAK1 and TRAF6, for K48 linked chains and
thus targets them for proteasomal degradation [1,2]. In a similar
manner CYLD replaces K63-linked chains on the important
scaffold protein on the NFkB pathway, IKK-c, for K48-linked
chains, thus targeting it for degradation and turning off the NFkB
pathway [3,4,5].
TRIM21 (Ro52/SSA1) is a member of the TRIM (Tripartite
Motif) family of single-protein E3 ligases and was originally
identified as an autoantigen prevalent in Systemic Lupus
Erythematosus (SLE). We have since identified TRIM21 as an
E3 ligase that negatively regulates type I IFN production
downstream of the pathogen recognition receptors (PRRs) TLR-
3, TLR-4, TLR-7 and TLR-9, innate immune receptors specific
for recognising viral and bacterial pathogens and inducing an
immune response appropriate to the pathogen detected [6,7,8].
Both TLR3 (recognising double stranded RNA viruses) and TLR4
(gram-negative bacterial LPS) respond by inducing pro-inflam-
matory cytokines such as TNF-a and IL-12, in addition to the
antiviral cytokines, the type I interferons (IFNs), via the activation
of transcription factors such as NFkB and the interferon regulatory
factors (IRFs), respectively. TRIM21 has been shown to bind and
regulate the stability of the IRF family of transcription factors,
including IRF3, IRF7, and IRF8, which are responsible for driving
type I IFN and IL-12 expression, downstream of these receptors
[6,7,9]. In the case of IRF3 and IRF7, TRIM21 in some studies
has been shown to promote degradation of these transcription
factors in order to turn off and limit the production of type I
interferons [6,7]. However, TRIM21 has also been shown to
stabilise IRF3 expression levels in response to sendai virus
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iinfection at the early phase of infection [10], thus indicating that
the role of TRIM21 in IRF regulation is complex. Regarding
IRF8, TRIM21 has been demonstrated to interact with and
ubiquitinate IRF8 leading to enhanced IL-12 production [9]. Two
groups have generated TRIM21-deficient mice, and whilst both
groups reported reduced ubiquitination of IRF family members
and enhanced expression of inflammatory cytokines, both showed
very differing phenotypes [11,12]. In keeping with a role for
TRIM21 in limiting TLR-induced inflammatory responses,
Espinosa et al have demonstrated that lack of functional TRIM21
in mice results in enhanced levels of circulating type I IFN, IL-23,
and enhanced responses to TLR7 and TLR9 ligands [12].
Interestingly, these mice develop lupus-like symptoms, including
hypergamma-globulinemia, autoantibodies to DNA, proteinuria,
and kidney pathology, consistent with the observations that both
type I IFNs and IL-23 are elevated in lupus patients and correlate
with both disease activity and pathology [12]. In contrast, when the
full gene for TRIM21 was disrupted by Yoshimi et al,n oo b s e r v a b l e
phenotype inimmune cells wasobserved, the authors suggesting that
upregulation of other TRIM family members acted to compensate
for the loss of TRIM21 [11]. TRIM21 is highly conserved across
species with 67% homology between the human and murine forms.
On balance, however it would appear that TRIM21 functions as a
negative regulator of IRF3 and IRF7 mediated cytokine production,
thus having important implications for systemic autoimmune
diseaseswhere type IIFNsplaysuchan importantrole.Interestingly,
genome wide association studies have mapped lupus susceptibility
genes to the genomic region that contains TRIM21, directly linking
TRIM21 with the disease [13,14].
Phosphorylation of ubiquitin E3 ligases has previously been
shown to be a key mechanism for regulating their activity. For
example, Pellino3, which functions as a direct negative regulator of
innate immune signalling by regulating IRAK degradation via its
E3 ligase activity [15], is in turn regulated by the serine/threonine
kinases IRAK1 and IRAK4, thus enhancing its E3 ubiquitin ligase
activity [16]. Tyrosine phosphorylation of E3 ligases has also been
implicated in the regulation of a number of different E3 ubiquitin
ligases, thereby potentially affecting the ability of the E3 ligase to
interact with either its substrates or its specific E2 thus regulating
its activity or potentially regulating the stability of the E3 ligase
itself. For example, mutation studies of c-Cbl have demonstrated a
number of tyrosines critical for regulating its function. Whilst
phosphorylation of C terminal tyrosine residues enhance interac-
tion with its substrates [17], phosphorylation of Y371 within the
linker region of the protein induces a conformational change in c-
Cbl that enhances its activity, thus breaking a negative
intramolecular interaction. Recent evidence also demonstrates
that phosphorylation of this tyrosine is critical for reducing the
affinity for c-Cbl for the E2 enzyme UbcH5b, resulting in
increased E3 ligase activity of c-Cbl [17,18,19].
To date however the mechanism by which TRIM21 activity is
regulated has not been investigated. Our work suggests that
tyrosine phosphorylation of TRIM21 positively regulates its
activity and identify tyrosine 393 in its PRY/SPRY domain as
the critical tyrosine in this respect. Critically, mutation of tyrosine
393 to phenylalanine results in the loss of activity of TRIM21 and
reduces its ability to interact with its substrate, IRF3. Our data
therefore suggests a novel mechanism by which TRIM21 activity
is regulated via promoting interaction with its substrate and
provides insights into TRIM21 activity that may be manipulated
in order to regulate type I IFN production in the treatment of
autoimmune disorders such as SLE, in which overproduction of
type I IFN and IL-23 play an important role in the pathogenesis of
the disease.
Results and Discussion
TRIM21 is tyrosine phosphorylated in response to TLR
stimulation
Work by our group and others has demonstrated a critical role
for TRIM21 in regulating TLR–driven cytokine production
[6,9,12]. To investigate potential means of regulating TRIM21
activity we investigated the possibility that TLR-stimulation of
cells induced tyrosine phosphorylation of TRIM21. Immortalised
murine Bone-Marrow Derived Macrophages (BMDMs) were
stimulated with both Poly I:C (20 mg/ml), a TLR3 agonist, and
LPS (1 mg/ml), a TLR4 agonist, for 0, 15, 30, and 60 mins.
Immunoprecipitation of tyrosine phosphorylated proteins from
cell lysates was performed and the presence of tyrosine
phosphorylated endogenous TRIM21 was determined by western
blotting. As can be seen in figure 1a, upper panel, both Poly I:C
and LPS stimulation resulted in a rapid and sustained phosphor-
ylation of TRIM21, with phospho-TRIM21 detectable as early as
15 mins post-stimulation. Both TLR3 and TLR4 stimulation
activated the cells as expected as measured by the induction of
phospho-TBK-1 and phospho-IkB, key proteins on the IRF3 and
NFkB pathways, respectively (figure 1a lower panels). Figure 1d
and 1e show the relevant densitometry analysis of these western
blots clearly showing the increase in tyrosine phosphorylation over
time following TLR3 and TLR4 stimulation respectively in
murine BMDMs. Tyrosine phosphorylation levels are normalised
to phospho-TRIM21 levels in resting cells. The plots are graphed
from the average of three separate experiments 6 standard error
of the mean. Recent work carried out by James et al has
determined TRIM21 to be an IgG receptor that binds normal
serum IgG through its PRY/SPRY domain [20]. Although
unlikely given the fact that Rhodes et al have recently shown that
mouse Abs do not bind to human TRIM21 [21], isotype-specific
IgG-agarose was used as a negative control in all immunoprecip-
itation experiments as can be seen in figure 1 and figure 2.
Having demonstrated that TRIM21 is tyrosine phosphorylated
in murine macrophages we next assessed its ability to be similarly
regulated in human peripheral blood mononuclear cells (PBMCs).
Accordingly PBMCs isolated from healthy volunteers were
stimulated with the TLR3 agonist Poly I:C for 0, 15, 30 and
60 minutes as indicated in figure 1b, and the TLR4 agonist LPS
for 0, 30, and 60 minutes as indicated in figure 1c, and the
phospho-status of TRIM21 determined as before. As with the
murine system, very low levels of tyrosine phosphorylated
TRIM21 is present in resting cells and stimulation with both
TLR3 and TLR4 agonists induced a rapid and sustained
phosphorylation of the E3 ligase, thus confirming the potential
importance of tyrosine phosphorylation of human TRIM21 in
regulating its activity. Figures 1f and 1g show the relevant
densitometry analysis of the western blot of figures 1b and 1c
clearly showing the increase in tyrosine phosphorylation over time
following TLR3 and TLR4 stimulation in primary human
PBMCs. Tyrosine phosphorylation levels are normalised to
phospho-TRIM21 levels in resting cells. The plots are graphed
from the average of three separate experiments 6 standard error
of the mean. A role for tyrosine kinases in LPS signalling has been
known since the first observation in 1991 that LPS treatment of
murine macrophages induced the expression of protein tyrosine
kinases Hck and Lyn [22]. In addition, TLR2 and 3 have been
reported to be inducibly phosphorylated on tyrosine residues on
ligand binding and one report has identified a tyrosine in MyD88
that is inducibly phosphorylated [23]. In each case the
phosphorylated tyrosine reportedly binds the p85 adaptor subunit
of phosphatidylinositol 3-kinase (PI3-K) and through it positively
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shown to be activated downstream of TLR4 and TLR8 and 9,
resulting in enhanced activation of NFkB and hence enhanced
pro-inflammatory cytokine production [24,25,26]. In addition Btk
has been shown to phosphorylate the adaptor molecule MyD88
Adaptor-like (Mal) post TLR2 and TLR4 activation, again
regulating NFkB activation [27]. As yet, the nature of the kinase
responsible for phosphorylating TRIM21 is unknown, although it
is tempting to speculate that Btk may be involved, acting post-
TLR stimulation to phosphorylate and hence regulate this critical
E3 ubiquitin ligase and promote its negative effects on TLR-
induced IFN production
TRIM21 is tyrosine phosphorylated on its PRY/SPRY
domain – a domain critical for interaction with substrates
Like other TRIM family members, TRIM21 is a single protein
E3 ligase with an N terminal RING domain (for interaction with
its cognate E2 enzyme), a central coiled-coil domain, and a C
terminal substrate interaction domain, in the case of TRIM21 a
PRY/SPRY domain. To determine which domain of TRIM21
was tyrosine phosphorylated we next performed overexpression
studies in HEK-293T cells, employing TRIM21 constructs missing
the RING domain (Dexon1) or the C terminal PRY/SPRY
domain (Dexon6) (figure 2a). As with endogenous TRIM21,
tyrosine phosphorylated proteins were enriched from cell lysates
and the presence of phosphorylated TRIM21 detected by western
blotting. As shown in figure 2b, full-length TRIM21 was tyrosine
phosphorylated following overexpression as expected. However,
whilst the mutant lacking the N-terminal RING domain was
tyrosine phosphorylated, the PRY/SPRY deletion mutant dem-
onstrated a complete inability to become phosphorylated,
indicating that tyrosine phosphorylation of TRIM21 occurs in
this region of the protein. The PRY/SPRY domain of TRIM21 is
well known to be essential for binding of substrates, such as IRF3,
IRF7, and IRF8 [7,9,28]. We have demonstrated here that
TRIM21 is tyrosine phosphorylated only in this domain indicating
a possible role for the tyrosine phosphorylation of TRIM21
regulating its ability to bind to IRF3, thus controlling further
downstream affects of TRIM21 activity.
Y393 is important for TRIM21 function– Using NetPhos
(http://www.cbs.dtu.dk/services/NetPhos/), tyrosine 343, 388
and 393 were strongly predicted to be phosphorylated (as shown
Figure 1. TRIM21 is tyrosine phosphorylated following TLR3 and TLR4 stimulation. (A) Immortalised BMDMs and (B, C) human PBMCs
were treated with indicated TLR ligands for the indicated time course. Tyrosine phosphorylated proteins were immunoprecipitated from lysates with
a-phospho-tyrosine agarose beads (Sigma). Tyrosine phosphorylation was assessed by immunoblotting for TRIM21. Figures are representative of 3
independent experiments. (D–G) Densitometric analysis was carried out on the western blots and the relative phosphorylation level of TRIM21 in
comparison to phospho-TRIM21 levels in resting cells was graphed from the average of three separate experiments 6 standard error of the mean
(S.E.M).
doi:10.1371/journal.pone.0034041.g001
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phenylalanine in order to assess their role in regulating TRIM21
function. Y343 and Y388 are conserved between human and
murine TRIM21 and are also predicted to be phosphorylated.
Interestingly, Y393 in human TRIM21 corresponds to S396 in
murine TRIM21 and this serine residue is also predicted to be
phosphorylated in murine TRIM21 (data not shown). As TRIM21
has previously been demonstrated to be a potent inhibitor of TLR-
driven IFN-b production [6], we employed an IFN-b promoter
reporter gene assay driven by an upstream activator of the
pathway, the adaptor protein TRIF, and assessed the effects of
each of the tyrosine mutants in this system. As expected from
previous reports, wild type full length TRIM21 dose dependently
inhibited IFN-b promoter activity, in keeping with its role as a
negative regulator of this response (figure 3b). Similarly transfec-
tion of cells with increasing amounts of Y343F resulted in a similar
inhibitory response, indicating that Y343 is not essential for
TRIM21 activity (figure 3c). In contrast we observed a lack of
inhibitory activity when Y388F and to a greater extent Y393F
mutants were assessed (figure 3d and 3e, respectively). Further
analysis to assess the effects of double (Y343,388F) and triple
(Y343,388,393F) mutants of TRIM21 was also conducted, with
both the double and triple mutants inhibiting the response in a
similar manner observed in the Y393F mutant as seen in figure 3f
and 3g respectively. To ensure all plasmids were expressing to a
similar level, expression analysis of the mutants was carried out.
Figure 3h illustrates that Y393F expresses to a higher level than
the other TRIM21 plasmids. However the increased expression of
Y393F does not lead to an increase in inhibition of IFN-b
promoter activity, emphasising that the lack of inhibition in this
regard is as a result of the tyrosine to phenylalanine mutation. All
other TRIM21 plasmids express to a similar level within the cell,
again suggesting that changes observed with these mutants in their
ability to inhibit TRIF-driven IFN-b promoter activity is indeed as
a result of the tyrosine to phenylalanine mutations and not due to
differences in protein expression. These results suggest that
tyrosine phosphorylation of Y393 is required for the activity of
TRIM21 in this context to be maintained. Previous reports of
tyrosine phosphorylation of E3 ligases such as c-Cbl have shown
that this modification can either alter intramolecular interactions
within the protein or enhance interaction with its substrate
[17,18]. Tyrosine phosphorylation may also alter subcellular
localisation of a protein or its stability [29]. Expression analysis of
our mutants indicated that stability of TRIM21 was not affected
(figure 3h), and given the fact that tyrosine phosphorylation
regulated the activity of the E3 ligase and occurred in the PRY/
SPRY domain, we hypothesised that phosphorylation at Y393 and
possibly Y388 may alter substrate interaction.
Y393 is essential for facilitating the interaction between
TRIM21 and its substrate IRF3
Importantly, based on the published crystal structure of
TRIM21 [20], Y388 and Y393 are associated with a known
substrate binding pocket and thus phosphorylation at these sites
may regulate interactions between TRIM21 and its known
substrates such as IRF3. To test this hypothesis, recombinant
PRY/SPRY domain TRIM21 (wild type and tyrosine mutants)
was constructed for use in pull-down experiments. This would
ensure that any observed effect of mutating the individual tyrosines
in TRIM21 on IRF3 binding was indeed a result of altered affinity
Figure 2. TRIM21 is tyrosine phosphorylated in the PRY/SPRY domain. (A) Schematic outline of WT TRIM21, TRIM21DExon1, and
TRIM21DExon6. (B) Tyrosine phosphorylated proteins were immunoprecipitated as before from cell lysates from HEK293T cells overexpressing
TRIM21 constructs and tyrosine phosphorylation of TRIM21 was assessed by immunoblotting with the anti-Xpress
TM antibody (Invitrogen).
doi:10.1371/journal.pone.0034041.g002
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(however unlikely) based on non-specific binding of TRIM21 to
antibody. Therefore recombinant PRY/SPRY TRIM21 proteins
(wild type, PRY/SPRY-Y343F, PRY/SPRY-Y388F and PRY/
SPRY-Y393F) were incubated individually with cell lysates from
HEK293T cells overexpressing FLAG-tagged IRF3 and the ability
of the recombinant protein to interact with IRF3 assessed by
western blotting. As shown in figure 3i, lane 2, wild type TRIM21
interacts with IRF3 as expected. In keeping with our reporter gene
analysis, PRY/SPRY-Y343F also interacted with IRF3 (lane 4),
confirming a lack of any functional role for this tyrosine in
regulating the ability of TRIM21 to interact with IRF3 and thus
inhibit its activity. PRY/SPRY-Y388F also interacted strongly
with IRF3, indicating that the reduced activity of Y388F, at lower
doses of plasmid DNA, on IFN-b promoter activity was not related
to its ability to interact with its substrate on this pathway IRF3
(lane 6). Perhaps further studies involving dose-response experi-
ments may elucidate a role for Y388 in the interaction of TRIM21
and IRF3. However, PRY/SPRY-Y393F had a greatly reduced
ability to interact with IRF3 (lane 8), suggesting that the lack of
inhibitory effect of this mutant on the IFN-b promoter was as a
direct result of the clear reduction in interaction occurring
between the mutant and the substrate IRF3. From analysis of
the crystal structure of the PRY/SPRY domain of TRIM21
elucidated by James et al, Y388 resides within an IgG binding
pocket and Y393 resides just outside this pocket [20]. Our results
would indicate that the interaction of TRIM21 and IRF3 is reliant
on Y393, and that the role that Y388 plays in the regulation of
TRIM21 activity is yet to be determined. Our results would also
indicate that the mutation of Y388 does not affect the ability of
TRIM21 to interact with IRF3, suggesting that the binding site of
IRF3 is not at Y388, but perhaps at Y393 which resides at a much
more accessible location in the PRY/SPRY domain of TRIM21.
Thus our studies reveal a novel mechanism for regulating the
activity of the E3 ligase TRIM21 via tyrosine phosphorylation of
tyrosine 393 thus promoting its interaction with its substrate IRF3.
In this respect, tyrosine phosphorylation of TRIM21 at this site
functions to turn on and off its activity. Recently a number of
groups have demonstrated the importance of TRIM21 in
regulating IFN and proinflammatory cytokine production down-
stream of anti-viral detection systems, via its ability to target the
IRF family of transcription factors [6,7,9]. Importantly, genetic
deletion of TRIM21 in mice resulted in the development of a
systemic autoimmune condition as a result of overproduction of
type I IFNs and the Th17 cell promoting cytokine, IL-23 [12].
Recently we have shown that TRIM21 acts as a negative regulator
of IL-23 downstream of TLR3 stimulation [30] and Al-Salleeh et al
have previously demonstrated a similar role for TRIM21
downstream of TLR7 and TLR9 activation [31]. Thus any
mechanism resulting in reduced activity of TRIM21 (whether by
presence of inactivating mutations in TRIM21, or via the ability of
autoantibodies against TRIM21 to inhibit E2 interactions [32])
would have the effect of reducing the effectiveness of TRIM21 as a
guardian against overproduction of type I IFNs and potentially IL-
23, thus contributing directly to the pathology of SLE. In this
respect, TRIM21 is an important target in the treatment of SLE.
Our novel findings regarding the regulation of TRIM21 activity
by tyrosine phosphorylation may have important implications with
regards to its possible manipulation in order to treat systemic
autoimmune conditions such as SLE. As with other E3 ligases that
are regulated by phosphorylation such as c-Cbl and the Pellino
family, knowledge regarding the kinases involved and the target




The HEK293T cell line and the J2 immortalised Bone-Marrow
derived macrophages (BMDMs) from wild type mice, a kind gift
from Dr. Egil Lien and Prof. Douglas Golenbock (UMASS
Medical School, Worcester, MA), were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% (v/v) fetal calf
serum and 1% penicillin-streptomycin. Primary human peripheral
mononuclear cells (PBMCs) were isolated from whole blood from
healthy donors, under ethical approval from Royal College of
Surgeons in Ireland research ethics committee REC269, using a
Ficoll gradient and cultured in RPMI-1640 media supplemented
with 10% (v/v) fetal calf serum and 1% penicillin-streptomycin.
Informed consent from all participants involved in this study was
obtained in a written manner. Participants involved in this study
were only recruited from, and experimentation conducted at,
Royal College of Surgeons in Ireland.
Plasmids and reagents
Xpress-tagged TRIM21, Xpress-tagged TRIM21DExon1,
Xpress-tagged TRIM21DExon6, and pGEX-PRY/SPRY
TRIM21 were gifts from Dr. David Rhodes (Cambridge Institute
for Medical Research, Cambridge, U.K.), and the Flag-tagged
pCMV-IRF3 and the IFN-b promoter construct were gifts from
Dr. Kate Fitzgerald (University of Massachusetts Medical School,
Worcester, MA). TRIM21 Y393F, TRIM21 Y343,388F, and
TRIM21 Y343,388,393F were generated by Genscript USA Inc.
(Piscataway, NJ 08854). Polyclonal Ab against TRIM21 was made
by Sigma Genosys. Primary antibodies used were anti-Xpress,
anti-V5 (Invitrogen Life Technologies), anti-phospho-IkB (Cell
Signalling), anti-phospho-TBK and anti-alpha-actinin (Santa Cruz
Biotechnologies), anti-Flag (Sigma), anti-GST (GE Healthcare),
and anti-b-actin (Abcam). Anti-phosphotyrosine agarose beads
were obtained from Sigma.
Site-directed mutagenesis
V5-TRIM21 was generated from cDNA and inserted into
pcDNA3.1 using the Gateway
TM vector system (Invitrogen Life
Technologies). The V5-TRIM21 and the pGEX-PRY/SPRY
TRIM21 tyrosine to phenylalanine mutants were generated from
the V5-TRIM21 plasmid and pGEX-PRY/SPRY TRIM21
plasmid using the QuikChange Lightning site-directed mutagen-
esis kit (Stratagene). The primers used for the mutagenesis are as
follows: Y343F, cactctggaaaacatttctgggaggtagatgtg (forward) and
cacatctacctcccagaaatgttttccagagtg (reverse); Y388F, gtggaacaaa-
Figure 3. Tyrosine 393 regulates IRF3 interaction and hence the activity of TRIM21. (A), Netphos data predicting potential tyrosine
phosphorylation sites in TRIM21. (B–G) TRIF-driven IFN-b reporter gene analysis was measured in HEK293T cells transfected with indicated TRIM21
plasmids. Kruskal-Wallis ANOVA analysis assessed relative fold increase of IFN-b promoter activity. * P,0.05 was considered significant and is
compared to TRIF driven IFN-b promoter activity alone. (H) Cell lysates prepared from HEK293T cells overexpressing WT TRIM21 and the indicated
mutants were assessed for expression of TRIM21 by western blotting with the anti-V5 antibody (Invitrogen). (I) Cell lysates prepared from HEK293T
cells overexpressing FLAG-IRF3 were incubated with recombinant GST-PRY/SPRY TRIM21 pre-coupled to GSH-sepharose beads as indicated and the
interaction between TRIM21and IRF3 assessed by immunoblotting. Figures are representative of three separate experiments.
doi:10.1371/journal.pone.0034041.g003
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gaatttttgtttgttccac (reverse); Y393F, gggattttcctggacttcgaggctgg-
catggtc (forward) and gaccatgccagcctcgaagtccaggaaaatccc (re-
verse).
Immunoprecipitation and Western Blot Analysis
Immunoblots were performed as previously described [25].
Cells were lysed on ice in 16Tris-HCl buffer (50 mM Tris-HCl,
pH 7.4, 1% Nonidet P40, 0.25% (w/v) sodium deoxycholate,
150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl
fluoride, 1 mM Na3VO4,1mg/ml pepstatin) followed by immu-
noprecipitation with anti-phosphotyrosine-conjugated agarose
beads (Sigma). For recombinant pulldowns, lysates were incubated
with 500 ng of GST-PRY/SPRY TRIM21 bound to GSH-
sepharose beads (Qiagen). Immunoprecipitates were analysed by
Western blot. Each blot is representative of three independent
experiments.
Reporter Gene Assays
HEK293T cells were seeded (10
5 cells/ml) onto 96-well plates
24 hrs pre-transfection with 50 ng of the indicated reporter
constructs and increasing amounts of the relevant TRIM21
constructs (10, 50, and 100 ng) as indicated. HEK293T cells were
also co-transfected with TRIF (50 ng) in order to drive the system.
Luciferase activity was standardised to Renilla luciferase plasmid
activity to normalise for transfection efficiency.
Statistical Analysis
A Kruskal-Wallis one-way analysis of variance was carried out
on non-parametric data using PASW Statistics version 18 from
SPSS (IBM Corporation, New York, USA). P,0.05 was
considered to be of significance.
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